The purpose of this study was to assess obstetrician-gynecologist utilization of low-dose aspirin for women at increased risk for hypertensive disorders of pregnancy. Further, the study evaluated prescribing practices in relation to speci c risk factor pro les in order to identify which women are at highest risk of not receiving recommended therapy. Methods:This was a retrospective cohort study reviewed and approved by the local Institutional Review Board. Electronic health records were reviewed to identify risk factors for preeclampsia. Women were eligible for aspirin prophylaxis if they had at least one "high" risk factor or multiple "moderate" risk factors.Associations of interest were addressed using Pearson Chi-squared tests and multinomial logistic regression.Results: 970 patients were included and 301 women (31%) met criteria for low-dose aspirin prophylaxis; of these, 92 (31%) were given this recommendation. Women eligible for prophylaxis by presence of multiple "moderate" risk factors alone were least likely (0-6%) to have a low-dose aspirin prescription. Conclusions for Practice:Low-dose aspirin is an underutilized tool for preventing preeclampsia. Women with a combination of "moderate" risk factors are most likely to not receive indicated aspirin prophylaxis. Efforts should be made to encourage broader uptake of the recommendations for aspirin prophylaxis among obstetriciangynecologists. Signi canceWhat is already known on this subject? Low-dose aspirin has been shown to reduce preeclampsia risk in pregnant women. This preventative measure has been recommended by prominent organizations including the American College of Obstetricians and Gynecologists and the United States Preventive Services Task Force. Yet despite widespread support of this recommendation, uptake is not universal among obstetric care providers. What this study adds?This study identi es those who are most likely to experience a missed opportunity for aspirin prophylaxis, thus providing a suggestion for where provider education or other efforts to increase adherence to this guideline may be most impactful. DeclarationsFunding: There was no nancial support obtained for the conduct of this research or preparation of this article for publication.Con icts of interest: The authors report no con icts of interest.Ethics approval: The project was reviewed and approved by the local Institutional Review Board (IRB) prior to commencement of the project.Consents: Waivers of informed consent or consent for publication were obtained from the IRB due to the retrospective nature of this chart review and since no patient-identifying information will be published.
Objective To describe the perinatal and neonatal outcomes of fetal laser ablation (FLA) for the treatment of twin-twin transfusion syndrome (TTTS) in our single center institution. Study design Retrospective study of 76 treated pregnant women. Procedural complications, perinatal and neonatal outcomes analyzed. Differences in outcomes between two procedural techniques, selective and Solomon, compared. Results FLA occurred at median gestational age (GA) of 20.8 weeks (IQR 18.1–22.9) with low incidence of procedural complications (5.3%). High survival rate with delivery of at least one neonate (96%) [95% CI: 88.9–99.2%]; 73.7% [95% CI: 62.3–83.1%] were twins. Median GA at birth was 33.1 weeks (IQR 28.0–35.0). Neonatal mortality and morbidities were 9.4% and 48.3% of cases respectively, and associated with lower GA. Solomon cases had comparatively higher median GA, and lower incidences of neonatal morbidities. Conclusion Our small single center study showed favorable outcomes for using the Solomon technique in the treatment of TTTS.
INTRODUCTION:Benefits of single- versus double-layer uterine closure at the time of cesarean delivery are unclear. We sought to evaluate the effect of single- versus double-layer closure in prior cesarean delivery at the time of cesarean hysterectomy for placenta accreta spectrum (PAS).METHODS:Retrospective study of patients with PAS and available prior cesarean delivery operative report were included in this IRB-approved cohort study. Those with history of single-layer closure were compared to those with history of double-layer closure, and the effect on maternal outcomes at the time of cesarean hysterectomy for PAS was evaluated. The primary outcome was surgical pathology diagnosis of percreta or increta versus accreta. Secondary outcomes included blood loss, intensive care unit admission, length of stay, and surgical time. Groups were compared via chi-square, Fisher’s exact, and t tests with logistic regression to evaluate for confounders.RESULTS:There were 36 participants available for review, 20 of whom (55.6%) had prior single-layer closure. Those with single-layer closure had a higher number of prior cesarean deliveries (2.5±1.1 versus 1.4±0.8, P=.003); otherwise, baseline characteristics were similar between groups. Diagnosis of percreta or increta at the time of cesarean delivery was more likely among those with single-layer closure (79.9% versus 41.7%, P=.056), although not statistically significant. Blood loss, operative time, and length of stay were higher as well, but these did not reach statistical significance (approximately 3,200 versus 1,900 mL, P=.138; 167 versus 140 minutes, P=.151; 4.8 versus 3.4 days, P=.059). In the regression analysis, after controlling for the number of prior cesarean deliveries and other potential confounders, the apparent increase in diagnosis of percreta or increta did not persist (adjusted odds ratio 0.55, 95% CI 0.20–1.53).CONCLUSION:No statistically significant benefit to prior single- versus double-layer closure was noted at the time of cesarean hysterectomy in those with PAS.
INTRODUCTION:Use of tranexamic acid (TXA) is beneficial in the setting of obstetric hemorrhage. We sought to understand whether patients with placenta accreta spectrum disorder benefit from TXA administration during cesarean hysterectomy.METHODS:This is an IRB-approved retrospective cohort study of participants with suspected placenta accreta spectrum undergoing cesarean hysterectomy in a single hospital system. Those who received TXA were compared to those who did not. The primary outcome was the rate of blood transfusion. Secondary outcomes included maternal intensive care unit (ICU) admission, massive transfusion, length of postoperative stay, operative time, and a composite of adverse maternal outcomes. Chi-square, t tests, and Fisher’s exact test were used to compare baseline characteristics, and a logistic regression was performed with possible confounders.RESULTS:A total of 87 participants met criteria for the study; among those were 35 (40.2%) who received TXA. Baseline characteristics between groups were similar. Although not statistically significant in univariable analysis, there was a trend for those who received TXA to have lower blood loss overall (∼2,000 mL versus ∼2,300 mL, P=.483) and be less likely to require transfusion (48.6% versus 69.2%, P=.053). Further, they were statistically less likely to undergo ICU admission (22.9% versus 60.4%, P=.001). There was no difference in the other secondary outcomes including the combined adverse maternal outcome (40.0% versus 44.2%, P=.695). After controlling for confounders, TXA administration was independently associated with decreased rates of blood transfusion (adjusted odds ratio [aOR] 0.23, 95% CI 0.08–0.68) and ICU admission (aOR 0.16, 95% CI 0.05–0.48).CONCLUSION:Tranexamic acid use in the setting of cesarean hysterectomy for PAS was associated with decreased risks of transfusion and ICU admission.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.